Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens

With the surge of antibiotic resistance in bacteria, the need for a larger arsenal of effective antibiotics and vaccines has drastically increased in the past decades. Antibiotics like vaccines can benefit from significant potentiation when used in combination with adjuvants. Antibiotic adjuvants ca...

Full description

Saved in:
Bibliographic Details
Main Authors: Chloé O. Sebilleau, Steven J. Sucheck
Format: Article
Language:English
Published: Open Exploration 2024-04-01
Series:Exploration of Drug Science
Subjects:
Online Access:https://www.explorationpub.com/uploads/Article/A100843/100843.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1825199574286860288
author Chloé O. Sebilleau
Steven J. Sucheck
author_facet Chloé O. Sebilleau
Steven J. Sucheck
author_sort Chloé O. Sebilleau
collection DOAJ
description With the surge of antibiotic resistance in bacteria, the need for a larger arsenal of effective antibiotics and vaccines has drastically increased in the past decades. Antibiotics like vaccines can benefit from significant potentiation when used in combination with adjuvants. Antibiotic adjuvants can allow for gram-positive bacteria (GPB) specific treatments to be used against gram-negative bacteria (GNB) infections, with minimal antimicrobial resistance (AMR). In the case of vaccines, they allow for modulation and increase of the immune response. Lipopeptides are molecules of choice because of their ability to activate specific cell surface receptors, penetrate the outer membrane of GNB, safety and ease of synthesis. This review explores the recent developments in lipopeptide adjuvants for antibiotics and vaccines, providing a roadmap on how to develop adjuvants to efficiently combat AMR. After a brief overview of bacterial resistance, lipopeptide adjuvants for antibiotics and vaccines are discussed, providing insights into stability, sources, and delivery methods. Findings discussed in this review could be applied to the development of safer, more effective adjuvants, that could expand the use or repurpose current antibiotics or improve vaccination results in future clinical trials.
format Article
id doaj-art-6955af6c946d49f0ba56861757ca7639
institution Kabale University
issn 2836-7677
language English
publishDate 2024-04-01
publisher Open Exploration
record_format Article
series Exploration of Drug Science
spelling doaj-art-6955af6c946d49f0ba56861757ca76392025-02-08T03:41:44ZengOpen ExplorationExploration of Drug Science2836-76772024-04-012220323310.37349/eds.2024.00043Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogensChloé O. Sebilleau0https://orcid.org/0009-0006-3417-385XSteven J. Sucheck1https://orcid.org/0000-0003-0082-3827Department of Chemistry and Biochemistry, University of Toledo, Toledo, OH 43606, USADepartment of Chemistry and Biochemistry, University of Toledo, Toledo, OH 43606, USAWith the surge of antibiotic resistance in bacteria, the need for a larger arsenal of effective antibiotics and vaccines has drastically increased in the past decades. Antibiotics like vaccines can benefit from significant potentiation when used in combination with adjuvants. Antibiotic adjuvants can allow for gram-positive bacteria (GPB) specific treatments to be used against gram-negative bacteria (GNB) infections, with minimal antimicrobial resistance (AMR). In the case of vaccines, they allow for modulation and increase of the immune response. Lipopeptides are molecules of choice because of their ability to activate specific cell surface receptors, penetrate the outer membrane of GNB, safety and ease of synthesis. This review explores the recent developments in lipopeptide adjuvants for antibiotics and vaccines, providing a roadmap on how to develop adjuvants to efficiently combat AMR. After a brief overview of bacterial resistance, lipopeptide adjuvants for antibiotics and vaccines are discussed, providing insights into stability, sources, and delivery methods. Findings discussed in this review could be applied to the development of safer, more effective adjuvants, that could expand the use or repurpose current antibiotics or improve vaccination results in future clinical trials.https://www.explorationpub.com/uploads/Article/A100843/100843.pdflipopeptideadjuvantvaccineantibiotic
spellingShingle Chloé O. Sebilleau
Steven J. Sucheck
Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens
Exploration of Drug Science
lipopeptide
adjuvant
vaccine
antibiotic
title Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens
title_full Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens
title_fullStr Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens
title_full_unstemmed Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens
title_short Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens
title_sort lipopeptide adjuvants for antibiotics and vaccines the future step in the fight against multidrug resistant and extensively drug resistant pathogens
topic lipopeptide
adjuvant
vaccine
antibiotic
url https://www.explorationpub.com/uploads/Article/A100843/100843.pdf
work_keys_str_mv AT chloeosebilleau lipopeptideadjuvantsforantibioticsandvaccinesthefuturestepinthefightagainstmultidrugresistantandextensivelydrugresistantpathogens
AT stevenjsucheck lipopeptideadjuvantsforantibioticsandvaccinesthefuturestepinthefightagainstmultidrugresistantandextensivelydrugresistantpathogens